Published in Proc Natl Acad Sci U S A on January 07, 1997
Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care (2011) 5.63
Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A (1998) 3.46
Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol (2002) 3.02
Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest (1997) 2.73
Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A (1999) 2.45
Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev (1999) 2.37
PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest (2002) 2.31
Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A (2000) 2.23
Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A (2000) 2.23
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer (2012) 2.06
Differentiation therapy of leukemia: 3 decades of development. Blood (2009) 2.02
Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia (1999) 1.78
Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics (2007) 1.71
Impaired adipogenesis and lipolysis in the mouse upon selective ablation of the retinoid X receptor alpha mediated by a tamoxifen-inducible chimeric Cre recombinase (Cre-ERT2) in adipocytes. Proc Natl Acad Sci U S A (2001) 1.69
Synergy between PPARgamma ligands and platinum-based drugs in cancer. Cancer Cell (2007) 1.60
Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis. Mol Cell Biol (2003) 1.60
PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev (2004) 1.58
Liposarcoma: molecular genetics and therapeutics. Sarcoma (2010) 1.55
The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg (2004) 1.55
Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells. Am J Pathol (2001) 1.48
Retracted A Role for PPARgamma in the Regulation of Cytokines in Immune Cells and Cancer. PPAR Res (2008) 1.48
Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer (2000) 1.47
The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency. Am J Pathol (2013) 1.45
De-novo identification of PPARgamma/RXR binding sites and direct targets during adipogenesis. PLoS One (2009) 1.39
Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer (2005) 1.39
SIRT1 is regulated by a PPAR{γ}-SIRT1 negative feedback loop associated with senescence. Nucleic Acids Res (2010) 1.35
A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer (2003) 1.31
Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro. Biochem J (2004) 1.27
The Role of PPARs in Cancer. PPAR Res (2008) 1.26
Transactivation by retinoid X receptor-peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimers: intermolecular synergy requires only the PPARgamma hormone-dependent activation function. Mol Cell Biol (1998) 1.25
Gamma (gamma) tocopherol upregulates peroxisome proliferator activated receptor (PPAR) gamma (gamma) expression in SW 480 human colon cancer cell lines. BMC Cancer (2003) 1.21
Molecular targets of dietary polyphenols with anti-inflammatory properties. Yonsei Med J (2005) 1.21
An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. Lab Invest (2010) 1.19
Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia (2001) 1.18
PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. J Clin Invest (2012) 1.16
Discrete roles for peroxisome proliferator-activated receptor gamma and retinoid X receptor in recruiting nuclear receptor coactivators. Mol Cell Biol (2000) 1.15
Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin Cancer Res (2002) 1.14
MiR-27b targets PPARγ to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene (2011) 1.14
Thiazolidinediones as anti-cancer agents. Cancer Ther (2008) 1.13
The multiple endocrine neoplasia type 1 (MEN1) tumor suppressor regulates peroxisome proliferator-activated receptor gamma-dependent adipocyte differentiation. Mol Cell Biol (2009) 1.08
Peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinoma. Br J Cancer (2001) 1.08
Induction of differentiation and peroxisome proliferator-activated receptor gamma expression in colon cancer cell lines by troglitazone. J Cancer Res Clin Oncol (2003) 1.07
Solid tumor differentiation therapy - is it possible? Oncotarget (2012) 1.05
Role of Peroxisome Proliferator-Activated Receptors in Inflammation Control. J Biomed Biotechnol (2004) 1.05
PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am J Physiol Renal Physiol (2010) 1.05
Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. Neoplasia (2006) 1.04
PPARγ and Oxidative Stress: Con(β) Catenating NRF2 and FOXO. PPAR Res (2012) 1.03
Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types. PPAR Res (2008) 1.01
PPAR gamma, bioactive lipids, and cancer progression. Front Biosci (Landmark Ed) (2012) 1.01
Adipocytes: impact on tumor growth and potential sites for therapeutic intervention. Pharmacol Ther (2013) 1.00
Advances in the targeted therapy of liposarcoma. Onco Targets Ther (2015) 0.99
The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells. Am J Pathol (2006) 0.99
Defective osteogenic differentiation in the development of osteosarcoma. Sarcoma (2011) 0.98
δ- and γ-tocopherols, but not α-tocopherol, inhibit colon carcinogenesis in azoxymethane-treated F344 rats. Cancer Prev Res (Phila) (2012) 0.98
Targeting PPARγ Signaling Cascade for the Prevention and Treatment of Prostate Cancer. PPAR Res (2012) 0.97
Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and disease. Comp Hepatol (2003) 0.97
Novel dedifferentiated liposarcoma xenograft models reveal PTEN down-regulation as a malignant signature and response to PI3K pathway inhibition. Am J Pathol (2013) 0.97
PPARgamma pathway activation results in apoptosis and COX-2 inhibition in HepG2 cells. World J Gastroenterol (2003) 0.96
Organotins are potent activators of PPARγ and adipocyte differentiation in bone marrow multipotent mesenchymal stromal cells. Toxicol Sci (2011) 0.95
A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer (2012) 0.95
Thiazolidinediones are partial agonists for the glucocorticoid receptor. Endocrinology (2008) 0.94
Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8/PPARgamma-negative thyroid tumours. Br J Cancer (2004) 0.93
Crosstalk of oncogenic and prostanoid signaling pathways. J Cancer Res Clin Oncol (2004) 0.92
Peroxisome proliferator-activated receptor γ agonists induce cell cycle arrest through transcriptional regulation of Kruppel-like factor 4 (KLF4). J Biol Chem (2012) 0.92
Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study. Clin Sarcoma Res (2013) 0.91
Characterization of liposarcoma cell lines for preclinical and biological studies. Sarcoma (2012) 0.90
PPARγ Promotes Growth and Invasion of Thyroid Cancer Cells. PPAR Res (2011) 0.90
Benign mesenchymal stromal cells in human sarcomas. Clin Cancer Res (2010) 0.90
Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer. Invest New Drugs (2002) 0.89
A Role for the PPARgamma in Cancer Therapy. PPAR Res (2008) 0.89
Phytanic acid, a novel activator of uncoupling protein-1 gene transcription and brown adipocyte differentiation. Biochem J (2002) 0.88
Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cells. BMC Cancer (2010) 0.88
PPARgamma Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention: A Pilot Study. PPAR Res (2010) 0.88
Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results. Cancers (Basel) (2013) 0.87
Stemness and inducing differentiation of small cell lung cancer NCI-H446 cells. Cell Death Dis (2013) 0.87
Biology of senescent liver peroxisomes: role in hepatocellular aging and disease. Environ Health Perspect (1999) 0.87
The Role of the PAX8/PPARgamma Fusion Oncogene in Thyroid Cancer. PPAR Res (2008) 0.86
Therapeutic Implications of PPARgamma in Human Osteosarcoma. PPAR Res (2010) 0.86
15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells. Br J Cancer (2002) 0.86
PPARγ activation following apoptotic cell instillation promotes resolution of lung inflammation and fibrosis via regulation of efferocytosis and proresolving cytokines. Mucosal Immunol (2015) 0.86
15d-PGJ2 inhibits cell growth and induces apoptosis of MCG-803 human gastric cancer cell line. World J Gastroenterol (2003) 0.86
Synergistic Effects of PPARgamma Ligands and Retinoids in Cancer Treatment. PPAR Res (2008) 0.86
Pleomorphic liposarcoma: clinical observations and molecular variables. Cancer (2011) 0.85
Pax-8-PPAR-γ fusion protein in thyroid carcinoma. Nat Rev Endocrinol (2014) 0.85
Human T-cell leukemia retrovirus-Tax protein is a repressor of nuclear receptor signaling. Proc Natl Acad Sci U S A (1999) 0.85
Chemotherapy and chemoprevention by thiazolidinediones. Biomed Res Int (2015) 0.85
Inhibition of human chondrosarcoma cell growth via apoptosis by peroxisome proliferator-activated receptor-gamma. Br J Cancer (2002) 0.84
Clinical Use of PPARgamma Ligands in Cancer. PPAR Res (2008) 0.84
Peroxisome proliferator-activated receptor gamma (PPARgamma) and colorectal carcinogenesis. J Cancer Res Clin Oncol (2007) 0.84
Activation of peroxisome proliferator-activated receptor gamma contributes to the survival of T lymphoma cells by affecting cellular metabolism. Am J Pathol (2007) 0.84
Effects of PPARγ Ligands on Leukemia. PPAR Res (2012) 0.84
Peroxisome proliferator activated receptor-γ and traumatic brain injury. Int J Clin Exp Med (2010) 0.84
Role of PPARs and Retinoid X Receptors in the Regulation of Lung Maturation and Development. PPAR Res (2007) 0.84
Activation of Penile Proadipogenic Peroxisome Proliferator-Activated Receptor gamma with an Estrogen: Interaction with Estrogen Receptor Alpha during Postnatal Development. PPAR Res (2008) 0.83
The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination. PPAR Res (2012) 0.83
To Live or to Die: Prosurvival Activity of PPARgamma in Cancers. PPAR Res (2008) 0.83
Modulation of PPAR-γ by Nutraceutics as Complementary Treatment for Obesity-Related Disorders and Inflammatory Diseases. PPAR Res (2012) 0.83
PPAR Ligands for Cancer Chemoprevention. PPAR Res (2008) 0.83
A rapid banding technique for human chromosomes. Lancet (1971) 27.45
Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell (1994) 17.58
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem (1995) 13.34
15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell (1995) 11.72
mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev (1994) 10.44
A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell (1995) 7.99
Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology (1996) 7.92
9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell (1992) 6.75
Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature (1992) 6.69
Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A (1994) 6.46
Cascade regulation of terminal adipocyte differentiation by three members of the C/EBP family of leucine zipper proteins. Genes Dev (1995) 6.03
Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature (1993) 5.69
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med (1994) 5.28
Acute promyelocytic leukemia. N Engl J Med (1993) 4.63
CCAAT/enhancer binding protein alpha is sufficient to initiate the 3T3-L1 adipocyte differentiation program. Proc Natl Acad Sci U S A (1994) 3.66
Conditional ectopic expression of C/EBP beta in NIH-3T3 cells induces PPAR gamma and stimulates adipogenesis. Genes Dev (1995) 3.63
Ectopic expression of the CCAAT/enhancer-binding protein alpha promotes the adipogenic program in a variety of mouse fibroblastic cells. Genes Dev (1994) 3.60
Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med (1991) 3.52
PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol (1995) 3.14
Regulation of adipocyte development. Annu Rev Nutr (1994) 3.09
Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. J Biol Chem (1993) 2.81
Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR gamma and RXR alpha. Nucleic Acids Res (1994) 2.58
Correlation between clinicopathological features and karyotype in lipomatous tumors. A report of 178 cases from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. Am J Pathol (1996) 2.42
Sarcomas and other malignancies of soft tissue, retroperitoneum, peritoneum, pleura, heart, mediastinum, and spleen. Cancer (1995) 2.25
Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: regulation by peroxisome proliferator-activated receptor gamma. Mol Cell Biol (1996) 2.21
Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr Opin Genet Dev (1995) 2.16
Diagnostic relevance of clonal cytogenetic aberrations in malignant soft-tissue tumors. N Engl J Med (1991) 1.99
Translocation t(12;16)(q13;p11) in myxoid liposarcoma and round cell liposarcoma: molecular and cytogenetic analysis. Cancer Res (1995) 1.91
Distinct stages in adipogenesis revealed by retinoid inhibition of differentiation after induction of PPARgamma. Mol Cell Biol (1996) 1.84
Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr (1995) 1.63
Chromosomal aberrations in soft tissue tumors. Relevance to diagnosis, classification, and molecular mechanisms. Am J Pathol (1994) 1.60
Myxoid liposarcoma. Experience with chemotherapy. Cancer (1994) 1.13
The prognostic value of histologic subtypes in primary extremity liposarcoma. Cancer (1989) 1.05
Ovarian granulosa-stromal cell tumors are characterized by trisomy 12. Am J Pathol (1991) 0.95
The prevention of adipose differentiation of 3T3-L1 cells caused by retinoic acid is elicited through retinoic acid receptor alpha. Life Sci (1994) 0.93
A new pathway for vitamin A. Understanding the pleiotropic effects of retinoids. Ann N Y Acad Sci (1992) 0.82
Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science (1993) 25.54
The nuclear receptor superfamily: the second decade. Cell (1995) 24.99
Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell (1999) 19.48
A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell (1998) 18.32
Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell (1994) 17.58
The RXR heterodimers and orphan receptors. Cell (1995) 12.33
Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature (2001) 11.72
15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell (1995) 11.72
A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature (1995) 11.18
The c-erb-A gene encodes a thyroid hormone receptor. Nature (1987) 10.53
mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev (1994) 10.44
PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell (1999) 10.08
PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell (1999) 9.74
Coincidence of the promoter and capped 5' terminus of RNA from the adenovirus 2 major late transcription unit. Cell (1978) 9.60
Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest (1995) 9.59
Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell (1991) 9.40
Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell (1997) 8.99
Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell (1991) 8.85
Nuclear receptors and lipid physiology: opening the X-files. Science (2001) 8.76
Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell (1997) 8.72
IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science (1996) 8.57
Transcriptional regulation of adipogenesis. Genes Dev (2000) 8.52
Identification of a receptor for the morphogen retinoic acid. Nature (1988) 8.32
PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell (1998) 7.91
Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature (1986) 7.81
Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A (1997) 7.52
Role of CBP/P300 in nuclear receptor signalling. Nature (1996) 7.36
Towards a molecular understanding of adaptive thermogenesis. Nature (2000) 7.04
AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem (1996) 6.93
9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell (1992) 6.75
Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature (1992) 6.69
Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature (1982) 6.56
ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev (1996) 6.54
A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell (1994) 6.52
Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A (1994) 6.46
Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol (2000) 6.40
Nuclear receptor that identifies a novel retinoic acid response pathway. Nature (1990) 6.23
PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med (2001) 6.09
PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem (2001) 5.85
Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell (1998) 5.78
Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature (1992) 5.76
A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell (2001) 5.76
Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature (1998) 5.63
Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell (1990) 5.59
KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res (2001) 5.40
ADD1: a novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation. Mol Cell Biol (1993) 5.34
Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell (1999) 5.23
Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature (1983) 5.20
Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med (1998) 5.16
Prospective acquisition correction for head motion with image-based tracking for real-time fMRI. Magn Reson Med (2000) 5.13
LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev (1995) 4.93
Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol Cell (1999) 4.89
Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J Clin Invest (1998) 4.85
A histone deacetylase corepressor complex regulates the Notch signal transduction pathway. Genes Dev (1998) 4.78
The initiation sites for RNA transcription in Ad2 DNA. Cell (1977) 4.76
Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell (1999) 4.76
Complex transcriptional units: diversity in gene expression by alternative RNA processing. Annu Rev Biochem (1986) 4.73
Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. Genes Dev (1992) 4.69
Functional domains of the human glucocorticoid receptor. Cell (1986) 4.68
Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes (1994) 4.66
Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science (1996) 4.61
Atypical and malignant solitary fibrous tumors in extrathoracic locations: evidence of their comparability to intra-thoracic tumors. Am J Surg Pathol (1998) 4.61
Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. Mol Cell (2001) 4.58
Determinants of target gene specificity for steroid/thyroid hormone receptors. Cell (1989) 4.56
Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science (1996) 4.50
Protein encoded by v-erbA functions as a thyroid-hormone receptor antagonist. Nature (1989) 4.47
Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature (1992) 4.42
Common DNA binding site for Fos protein complexes and transcription factor AP-1. Cell (1988) 4.38
Activation of PPARgamma coactivator-1 through transcription factor docking. Science (1999) 4.33
Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science (1987) 4.32
A transcriptional switch mediated by cofactor methylation. Science (2001) 4.32
Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. Nature (1982) 4.30
SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev (1998) 4.19
Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1. Nat Med (2001) 4.19
Molecular cloning of mRNA from 3T3 adipocytes. Regulation of mRNA content for glycerophosphate dehydrogenase and other differentiation-dependent proteins during adipocyte development. J Biol Chem (1983) 4.14
Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A (1994) 4.08
Multiple and cooperative trans-activation domains of the human glucocorticoid receptor. Cell (1988) 4.00
Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Genes Dev (2000) 4.00
Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc Natl Acad Sci U S A (2001) 3.96
TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol (2000) 3.92
Identification of a nuclear receptor that is activated by farnesol metabolites. Cell (1995) 3.92
Nucleoprotein complexes that regulate gene expression in adipocyte differentiation: direct participation of c-fos. Cell (1987) 3.89
PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science (2000) 3.87
A direct repeat in the cellular retinol-binding protein type II gene confers differential regulation by RXR and RAR. Cell (1991) 3.87